Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


One up, one down for CSL

Posted 6 April 2021 PM

CSL's acquisition of a one dose haemophilia B therapy from Dutch biotech UniQure appears set to pay off after a cancer scare around the program was effectively quashed.

According to UniQure, an independent investigation into a case of hepatocellular carcinoma (HCC) diagnosed in one patient in the HOPE-B pivotal trial found it was "highly unlikely" there was a link to its treatment etranacogene dezaparvovec (AMT-061).

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
All fine, nothing to see here
How politics made a mess of the rollout
Special Report
PBAC July Agenda
Committee to assess 36 submissions
Approvals Action
First copy of gout drug
Plus new formulations of PBS-listed drugs
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas